US Rx Drug Prices Rose 2.6% In 1994

23 January 1995

At the wholesale level, US prescription drug prices saw a 2.6% increase during 1994, reports the Bureau of Labor Statistics in its Producer Price Index. This compares with a rise of 4.1% for the top 500 Rx drugs sold in community retail pharmacists, quoted by the National Association of Chain Drug Stores quarterly Prime Index (Marketletter January 9).

The BLS 1994 figures confirm the downward trend of US pharmaceutical prices over the past five years. In 1989, the PPI for prescription medicines was up 9.5%, in 1990 it rose 8.1%, in 1991 it was 7.9% higher, in 1992 it rose 6.8% and in 1993 it increased by just 3%.

According to the Pharmaceutical Research and Manufacturers of America, the lower rate of drug price rises is the result of competitive, market-driven cost containment, which has been seen throughout the 1990s. Moreover, it says, companies have made pledges to keep price rises down due to pressure from Congress and the prospects of health care reform.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight